Literature DB >> 14708870

Microcirculatory dysfunction during intestinal ischemia-reperfusion.

M Boros1.   

Abstract

Oxido-reductive stress is a crucial factor of the tissue response during ischemia-reoxygenation injuries. Reperfusion affects primarily the microvasculature in a manner consistent with an acute inflammatory reaction. In this respect, the salient data suggest an important connection between endothelial cell-derived humoral mediators and the perivascular mast cell system. Increased endothelin-1 and decreased nitric oxide formation, mast cell degranulation and leukocyte accumulation coexist in gastrointestinal ischemia-reperfusion syndromes too. Constitutively produced nitric oxide inhibits, while increasingly formed endothelin-1 significantly enhances the degranulation of the intestinal mast cells. The endothelin-A receptor-dependent mast cell degranulation per se plays a secondary role in reperfusion-induced structural injury, but contributes significantly to leukocyte recruitment into the reperfused intestinal mucosa. It is conceivable therefore, that the nitric oxide--endothelin-1--mast cell cycle is involved in the mechanism of ischemia-reperfusion-induced endothelial cell-leukocyte interactions, where mast cells act to amplify the process of leukocyte sequestration. The alteration in the balance between endothelial cell-derived proadhesive vasoconstrictor and antiadhesive vasodilator factors exerts a significant influence on the mucosal integrity, and the antagonism of endothelin-A receptor activation in this setting tips the equilibrium toward tissue salvage.

Entities:  

Mesh:

Year:  2003        PMID: 14708870     DOI: 10.1556/APhysiol.90.2003.4.1

Source DB:  PubMed          Journal:  Acta Physiol Hung        ISSN: 0231-424X


  8 in total

Review 1.  Mechanisms of I/R-Induced Endothelium-Dependent Vasodilator Dysfunction.

Authors:  Ronald J Korthuis
Journal:  Adv Pharmacol       Date:  2017-12-08

Review 2.  Reactive species-induced microvascular dysfunction in ischemia/reperfusion.

Authors:  Hong Yu; Ted Kalogeris; Ronald J Korthuis
Journal:  Free Radic Biol Med       Date:  2019-03-05       Impact factor: 7.376

3.  Pretreatment of cromolyn sodium prior to reperfusion attenuates early reperfusion injury after the small intestine ischemia in rats.

Authors:  Zi-Qing Hei; Xiao-Liang Gan; Gang-Jian Luo; Shang-Rong Li; Jun Cai
Journal:  World J Gastroenterol       Date:  2007-10-14       Impact factor: 5.742

4.  Different patterns of intestinal response to injury after arterial, venous or arteriovenous occlusion in rats.

Authors:  Francisco Javier Guzmán-de la Garza; Carlos Rodrigo Cámara-Lemarroy; Gabriela Alarcón-Galván; Paula Cordero-Pérez; Linda Elsa Muñoz-Espinosa; Nancy Esthela Fernández-Garza
Journal:  World J Gastroenterol       Date:  2009-08-21       Impact factor: 5.742

5.  Systemic phosphatidylcholine pretreatment protects canine esophageal mucosa during acute experimental biliary reflux.

Authors:  Gabor Eros; Jozsef Kaszaki; Miklos Czobel; Mihaly Boros
Journal:  World J Gastroenterol       Date:  2006-01-14       Impact factor: 5.742

6.  Comparison of the chloride channel activator lubiprostone and the oral laxative Polyethylene Glycol 3350 on mucosal barrier repair in ischemic-injured porcine intestine.

Authors:  Adam-J Moeser; Prashant-K Nighot; Birgit Roerig; Ryuji Ueno; Anthony-T Blikslager
Journal:  World J Gastroenterol       Date:  2008-10-21       Impact factor: 5.742

7.  Protective effects of ginsenoside Rg1 on intestinal ischemia/reperfusion injury-induced oxidative stress and apoptosis via activation of the Wnt/β-catenin pathway.

Authors:  Guo Zu; Jing Guo; Ningwei Che; Tingting Zhou; Xiangwen Zhang; Guangzhi Wang; Xiaofeng Tian
Journal:  Sci Rep       Date:  2016-12-02       Impact factor: 4.379

8.  Computed Tomography Perfusion Imaging Detection of Microcirculatory Dysfunction in Small Intestinal Ischemia-Reperfusion Injury in a Porcine Model.

Authors:  Haifeng Shi; Ruokun Li; Jinwei Qiang; Ying Li; Li Wang; Rongxun Sun
Journal:  PLoS One       Date:  2016-07-26       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.